Asset profile
BSI-045B
Monoclonal antibody
Evidence outlook · lead readout
NCT05932654 · Atopic Dermatitis
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT05932654: The study treated 22 participants in one open-label, non-randomized arm without a placebo or active comparator. Its clinical primary efficacy endpoint was reported for 17 participants, but there was no controlled comparison or formal primary endpoint test, so the favorable response rate provides limited evidence of efficacy.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.